



## Veracyte to Present at the UBS Global Healthcare Conference

May 9, 2019

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 9, 2019-- [Veracyte, Inc.](#) (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that Bonnie H. Anderson, chairman and chief executive officer, is scheduled to present at the UBS Global Healthcare Conference in New York City on Monday, May 20, 2019 at 9:30 a.m. EDT.

The link to the live audio webcast of the company's presentation will be available by visiting Veracyte's website at <http://investor.veracyte.com/events-presentations>. A replay of the webcast will be available for 90 days following the conclusion of the live presentation broadcast.

### About Veracyte

Veracyte (Nasdaq: VCYT) is a leading genomic diagnostics company that improves patient care by providing trustworthy and actionable answers to challenging clinical questions. The company's products uniquely combine advanced genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward, informing both diagnosis and treatment decisions without the need for costly, risky surgeries that are often unnecessary. Since its founding in 2008, Veracyte has commercialized five genomic tests which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis. Veracyte is based in South San Francisco, California. For more information, please visit [www.veracyte.com](http://www.veracyte.com) and follow the company on Twitter (@veracyte).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190509005849/en/>

Source: Veracyte, Inc.

### Veracyte Investor & Media Contact:

Angie McCabe  
Vice President, Investor Relations & Corporate Communications  
650-243-6371  
[angie@veracyte.com](mailto:angie@veracyte.com)